Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Farampator (CX-691) (CX-691;Org24448) is a positive modulator of AMPA receptor.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 37.00 | |
2 mg | In stock | $ 50.00 | |
5 mg | In stock | $ 80.00 | |
10 mg | In stock | $ 117.00 | |
25 mg | In stock | $ 238.00 | |
50 mg | In stock | $ 413.00 | |
100 mg | In stock | $ 615.00 | |
500 mg | In stock | $ 1,320.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 88.00 |
Description | Farampator (CX-691) (CX-691;Org24448) is a positive modulator of AMPA receptor. |
In vitro | CX691 attenuates a scopolamine-induced impairment of cued fear conditioning following acute administration (0.1 mg/kg p.o.) and a temporally induced deficit in novel object recognition following both acute (0.1 and 1.0 mg/kg p.o.) and sub-chronic (bi-daily for 7 days) administration (0.01, 0.03, 0.1 mg/kg p.o.). It also improves attentional set-shifting following sub-chronic administration (0.3 mg/kg p.o.). Farampator (500 mg) unequivocally improves short-term memory but appeares to impair episodic memory. Furthermore, it tends to decrease the number of switching errors in the CTMT. Drug-induced side effects (SEs) included headache, somnolence and nausea. Subjects with SEs has significantly higher plasma levels of farampator than subjects without SEs. Farampator has potential in treating disorders characterised by cognitive deficits such as Alzheimer's disease and schizophrenia. |
In vivo | Farampator holds promise for managing cognitive deficits associated with conditions like Alzheimer's disease and schizophrenia. It mitigates scopolamine-induced cued fear conditioning impairment with a single dose (0.1 mg/kg p.o.) and rectifies deficits in novel object recognition after both acute (0.1 and 1.0 mg/kg p.o.) and sub-chronic (twice daily for 7 days at doses of 0.01, 0.03, 0.1 mg/kg p.o.) administrations. Moreover, farampator enhances attentional set-shifting with sub-chronic use (0.3 mg/kg p.o.)[1]. Notably, at a 500 mg dosage, farampator consistently improves short-term memory, albeit with a tendency to impair episodic memory and reduces switching errors in the CTMT. Reported side effects (SEs) include headache, somnolence, and nausea, with subjects exhibiting SEs displaying significantly higher plasma levels of farampator compared to those without SEs[2]. |
Synonyms | Org24448, CX-691 |
Molecular Weight | 231.25 |
Formula | C12H13N3O2 |
CAS No. | 211735-76-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (216.21 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Farampator 211735-76-1 Membrane transporter/Ion channel Neuroscience GluR iGluR inhibit Org 24448 Org-24448 Org24448 Inhibitor CX 691 CX691 Ionotropic glutamate receptors CX-691 inhibitor